Oxaliplatin-based chemotherapy plays an important role in the treatment of colorectal liver metastases. Oxaliplatin, however, causes sinusoidal obstruction syndrome (SOS), which is characterized by portal hypertension, splenomegaly, thrombocytopenia, and liver dysfunction. SOS is diagnosed histopathologically by disruption of the sinusoidal endothelium, collagen deposition, fbrosis especially around zone 3, dilatation of the sinusoidal space and congestion. This study assessed the characteristics of a rat model of SOS. SOS was induced in rats by administration of monocrotaline (MCT). Blood chemistries and macroscopic and microscopic fndings were compared in rats administered MCT and vehicle (control group). Levels of expression in the liver...
Background: In advanced metastatic colorectal adenocarcinoma, the addition of a neo-adjuvant systemi...
SummarySinusoidal obstruction syndrome (SOS) is characterized by damage to small hepatic vessels aff...
Vreuls C P H, Van Den Broek M A, Winstanley A, Koek G H, Wisse E, Dejong C H, Olde Damink S W M, Bos...
13301甲第4590号博士(医学)金沢大学博士論文本文Full 以下に掲載:MOLECULAR MEDICINE REPORTS 15 pp.3147-3152 2017. SPANDIDOS PU...
Background & AimsSinusoidal obstruction syndrome (SOS) following oxaliplatin based chemotherapy can ...
AIMS: Oxaliplatin is an important chemotherapeutic agent, used in the treatment of hepatic colorecta...
13301甲第4682号博士(医学)金沢大学博士論文本文Full 以下に掲載:Journal of Gastroenterology and Hepatology 33(4) pp.950-957 2...
Background & aimsSinusoidal obstruction syndrome (SOS) following oxaliplatin based chemotherapy can ...
BACKGROUND AND OBJECTIVES: Oxaliplatin is a chemotherapeutic drug for colorectal adenocarcinoma able...
Sinusoidal obstruction syndrome (SOS), previously known as veno-occlusive disease, is relatively rar...
Oxaliplatin-based chemotherapy is widely used to treat advanced colorectal cancer (CRC). Sinusoidal ...
<div><p>Oxaliplatin-based chemotherapy is widely used to treat advanced colorectal cancer (CRC). Sin...
Portal sinusoidal vascular disease is a presinusoidal cause of portal hypertension (PHT) of unknown ...
PhD ThesisOxaliplatin based chemotherapy has demonstrated remarkable efficacy in down staging color...
BACKGROUND: Sinusoidal obstruction syndrome (SOS) occurs in 50-70% of patients after oxaliplatin tre...
Background: In advanced metastatic colorectal adenocarcinoma, the addition of a neo-adjuvant systemi...
SummarySinusoidal obstruction syndrome (SOS) is characterized by damage to small hepatic vessels aff...
Vreuls C P H, Van Den Broek M A, Winstanley A, Koek G H, Wisse E, Dejong C H, Olde Damink S W M, Bos...
13301甲第4590号博士(医学)金沢大学博士論文本文Full 以下に掲載:MOLECULAR MEDICINE REPORTS 15 pp.3147-3152 2017. SPANDIDOS PU...
Background & AimsSinusoidal obstruction syndrome (SOS) following oxaliplatin based chemotherapy can ...
AIMS: Oxaliplatin is an important chemotherapeutic agent, used in the treatment of hepatic colorecta...
13301甲第4682号博士(医学)金沢大学博士論文本文Full 以下に掲載:Journal of Gastroenterology and Hepatology 33(4) pp.950-957 2...
Background & aimsSinusoidal obstruction syndrome (SOS) following oxaliplatin based chemotherapy can ...
BACKGROUND AND OBJECTIVES: Oxaliplatin is a chemotherapeutic drug for colorectal adenocarcinoma able...
Sinusoidal obstruction syndrome (SOS), previously known as veno-occlusive disease, is relatively rar...
Oxaliplatin-based chemotherapy is widely used to treat advanced colorectal cancer (CRC). Sinusoidal ...
<div><p>Oxaliplatin-based chemotherapy is widely used to treat advanced colorectal cancer (CRC). Sin...
Portal sinusoidal vascular disease is a presinusoidal cause of portal hypertension (PHT) of unknown ...
PhD ThesisOxaliplatin based chemotherapy has demonstrated remarkable efficacy in down staging color...
BACKGROUND: Sinusoidal obstruction syndrome (SOS) occurs in 50-70% of patients after oxaliplatin tre...
Background: In advanced metastatic colorectal adenocarcinoma, the addition of a neo-adjuvant systemi...
SummarySinusoidal obstruction syndrome (SOS) is characterized by damage to small hepatic vessels aff...
Vreuls C P H, Van Den Broek M A, Winstanley A, Koek G H, Wisse E, Dejong C H, Olde Damink S W M, Bos...